Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Investor Presentation (March 2025)
17 slides from Bactiguard Holding Ab's investor presentation, Mar 6, 2025
Slide 1: Updated strategic and financial targets
Updated strategic and financial targets 6 March 2025 Christine Lind, CEO Patrick Bach, CFO
Slide 2: The new Bactiguard in brief
The new Bactiguard in brief Q&A advanced technology to established license potential in future prevent medical device partnerships with global license partnerships related infections MedTech giants across therapeutic areas “become global standard of care for preventing medical device related infecti
Slide 3: The issue of healthcare associated infections
The issue of healthcare associated infections • 1 in 10 patients worldwide affected by healthcare associated infections (HAI)1 • 40-60% of all HAIs caused by medical devices2 • Up to 50% of HAIs estimated to be preventable3 • Costs associated with HAIs (ie extended hospital stays and additional trea
Slide 4: Full-year 2024 key figures and achievements
Full-year 2024 key figures and achievements License focused strategy delivered increased revenues and profitability Key figures for 2024 (2023) The new Bactiguard • Delivered on strategic shift – license focus Revenues 261.9 (223.2) MSEK • Increased revenues and EBITDA profitability • Positive Cash
Slide 5: Review and outcome – targets and therapeutic areas
REVIEW AND OUTCOME – TARGETS AND THERAPEUTIC AREAS
Slide 6: A data driven approach to shape our long-range plan
A data driven approach to shape our long-range plan Market review Process review Modeling Review of external data sources incl. Analysis of approval timelines across Dynamic, granular financial modelling +15 therapeutic areas, +100 clinical therapeutic areas and medical classes of potential new appl
Slide 7: Updated strategic and financial targets
Updated strategic and financial targets Scalability and operational leverage of business model increases over time >10 >200 >600 At least ten application areas EBITDA of at least SEK 200 Revenues of at least SEK in either exclusivity or license million by year-end 2030 600 million by year-end 2030 p
Slide 8: Focus therapeutic areas for the license business
Focus therapeutic areas for the license business Areas with high unmet medical needs Orthopedics Vascular access Cardiology Neurology Urology Hip Implants Central Venous Catheter Deep Brain Stimulator Application areas Ventricular Assisted Device Foley Catheter Knee Implants Peripherally Inserted Ce
Slide 9: Go-to-market – indicative timelines
Go-to-market – indicative timelines From early-stage testing to commercialization takes several years Collaboration within Medical devices Class II Average 5 years • Basic feasibility and performance tests • Process/product development • Clinical studies and outcome Medical devices • Regulatory requ
Slide 10: Wound Management's contribution to financial targets
Wound Management’s contribution to financial targets Continued profitable double-digit growth and from existing and expansion into new markets +14% 61 54 41 44 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10
Slide 11: Financial profile develops favorably over time
Financial profile develops favorably over time Double-digit growth and margin expansion driven by existing business towards 2030 Projected revenues from existing business and new partnerships >600 MSEK • Grow by focusing on select application areas in strategic therapeutic areas with the highest 1/3
Slide 12: Business model enables significant operational leverage
Business model enables significant operational leverage Significant scale beyond 2030 as royalties from new application areas mature Illustrative revenues from existing business and new partnerships • Business model’s inherent operating leverage drives substantial EBITDA expansion, especially 3/4 fr
Slide 13: Status today and framework ahead
STATUS TODAY AND FRAMEWORK AHEAD
Slide 14: Announcing progress across partnership phases
Announcing progress across partnership phases Exclusivity partnerships and License partnerships announced with partner name Material transfer Application development Exclusivity partnership License partnership agreement partnership Orthopedics Vascular access Cardiology Neurology Urology Other 14
Slide 15: The new Bactiguard – strategic focus areas and priorities
The new Bactiguard – strategic focus areas and priorities Be the premier partner for leading MedTech companies R&D Wound License Medical Management partnerships portfolio Regulatory Advance current and develop Invest further in above key Grow profitably and new partnerships knowledge areas expand in
Slide 16: Today's presentation in summary
Today’s presentation in summary Key takeaways Strategic and financial targets • Rigorous approach to define the long-range plan Partnership development Have at least ten application areas in either exclusivity • Strategic therapeutic areas: Orthopedics, Vascular partnership or license partnership by
Slide 17: Q&A
Q&A to champion a healthier world by preventing infections